The CEO of Arcturus on data presented today for an inhaled mRNA therapy at the 47th European Cystic Fibrosis Conference
Joseph Payne describes data from the first four patients with CF to receive this inhaled mRNA at #ECFS2024. He also summarizes Arcturus' approach to mRNA and LNPs, and the company's broader pipeline.